Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT03650764 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Ramucirumab
DRUG: Pembrolizumab
OTHER: EORTC QLQ-30
OTHER: FACT H&N
PROCEDURE: Peripheral blood

Sponsor

Washington University School of Medicine

Collaborators

[object Object]